Kathleen M Powis1, Laura Smeaton, Michael D Hughes, Esther A Tumbare, Sajini Souda, Jennifer Jao, Kathleen E Wirth, Joseph Makhema, Shahin Lockman, Wafaie Fawzi, Max Essex, Roger L Shapiro. 1. aDepartments of Medicine and Pediatrics, Massachusetts General Hospital, Boston bDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA cBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana dDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA eElizabeth Glaser Pediatric AIDS Foundation, Harare, Zimbabwe fFaculty of Medicine, University of Botswana, Gabarone, Botswana gDivisions of Infectious Diseases and General Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine, Mount Sinai, New York City, New York, USA hDepartment of Epidemiology, Harvard T.H. Chan School of Public Health iInfectious Disease Division, Brigham and Women's Hospital, Boston jDepartments of Global Health and Population, Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health kBeth Israel Deaconess Medical Center, Infectious Diseases Department, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To assess associations between in-utero triple antiretrovirals (cART) versus zidovudine (ZDV) monotherapy exposure and growth among HIV-uninfected children of HIV-infected women in Botswana. DESIGN: Secondary retrospective data analysis from two randomized intervention trials of mother-to-child HIV transmission prevention. METHODS: The Mashi and Mma Bana studies enrolled HIV-infected pregnant women, following their children through 24 months of age. This analysis includes singleton, full-term, HIV-exposed uninfected children. Mothers received cART or ZDV at least 2 weeks predelivery, and breastfed up to 6 months. Weight-for-age (WAZ), length-for-age (LAZ) and weight-for-length (WLZ) z-scores were derived. Mean z-scores were compared by exposure group at 24 months (t-test, linear regression). RESULTS: Of 819 children, 303 were ZDV- and 516 cART-exposed in utero. Maternal median enrolment CD4 was higher among ZDV versus cART-treated mothers (393 versus 324 cells/μl; P < 0.0001). Median duration of antepartum antiretroviral use was shorter among ZDV-treated women (5.7 versus 12.0 weeks; P < 0.0001). Median months breastfed were similar (5.9 and 6.0; P = 0.43). At 24 months, mean LAZ and WAZ were significantly lower among cART-exposed children (LAZ -1.01 versus -0.74; P = 0.003) (WAZ -0.53 versus -0.30; P = 0.002) in unadjusted analyses. Adjusting for maternal CD4, viral load, enrolment site and maternal anthropometric measures, cART-exposed children had significantly lower LAZ and WAZ at 24 months (P = 0.0004 for both). CONCLUSION: At 24 months, in-utero cART-exposed children had significantly lower LAZ and WAZ. Poor growth impacts childhood and adult mortality. These findings raise concerns for potential lasting health impacts among HIV-exposed uninfected children with in-utero cART exposure.
RCT Entities:
OBJECTIVE: To assess associations between in-utero triple antiretrovirals (cART) versus zidovudine (ZDV) monotherapy exposure and growth among HIV-uninfectedchildren of HIV-infectedwomen in Botswana. DESIGN: Secondary retrospective data analysis from two randomized intervention trials of mother-to-child HIV transmission prevention. METHODS: The Mashi and Mma Bana studies enrolled HIV-infected pregnant women, following their children through 24 months of age. This analysis includes singleton, full-term, HIV-exposed uninfected children. Mothers received cART or ZDV at least 2 weeks predelivery, and breastfed up to 6 months. Weight-for-age (WAZ), length-for-age (LAZ) and weight-for-length (WLZ) z-scores were derived. Mean z-scores were compared by exposure group at 24 months (t-test, linear regression). RESULTS: Of 819 children, 303 were ZDV- and 516 cART-exposed in utero. Maternal median enrolment CD4 was higher among ZDV versus cART-treated mothers (393 versus 324 cells/μl; P < 0.0001). Median duration of antepartum antiretroviral use was shorter among ZDV-treated women (5.7 versus 12.0 weeks; P < 0.0001). Median months breastfed were similar (5.9 and 6.0; P = 0.43). At 24 months, mean LAZ and WAZ were significantly lower among cART-exposed children (LAZ -1.01 versus -0.74; P = 0.003) (WAZ -0.53 versus -0.30; P = 0.002) in unadjusted analyses. Adjusting for maternal CD4, viral load, enrolment site and maternal anthropometric measures, cART-exposed children had significantly lower LAZ and WAZ at 24 months (P = 0.0004 for both). CONCLUSION: At 24 months, in-utero cART-exposed children had significantly lower LAZ and WAZ. Poor growth impacts childhood and adult mortality. These findings raise concerns for potential lasting health impacts among HIV-exposed uninfected children with in-utero cART exposure.
Authors: Kathleen M Powis; Laura Smeaton; Anthony Ogwu; Shahin Lockman; Scott Dryden-Peterson; Erik van Widenfelt; Jean Leidner; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Robert E Black; Cesar G Victora; Susan P Walker; Zulfiqar A Bhutta; Parul Christian; Mercedes de Onis; Majid Ezzati; Sally Grantham-McGregor; Joanne Katz; Reynaldo Martorell; Ricardo Uauy Journal: Lancet Date: 2013-06-06 Impact factor: 79.321
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Ibironke Olofin; Christine M McDonald; Majid Ezzati; Seth Flaxman; Robert E Black; Wafaie W Fawzi; Laura E Caulfield; Goodarz Danaei Journal: PLoS One Date: 2013-05-29 Impact factor: 3.240
Authors: Lindsey M Locks; Karim P Manji; Roland Kupka; Enju Liu; Rodrick Kisenge; Christine M McDonald; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Date: 2016-11-07 Impact factor: 4.406
Authors: Karl W le Roux; Joan Christodoulou; Emily C Davis; Linnea Stansert Katzen; Elaine Dippenaar; Mark Tomlinson; Mary Jane Rotheram-Borus Journal: AIDS Care Date: 2019-10-22
Authors: Jennifer Jao; Laura Freimanis; Marisa M Mussi-Pinhata; Rachel A Cohen; Jacqueline Pontes Monteiro; Maria Leticia Cruz; Andrea Branch; Rhoda S Sperling; George K Siberry Journal: Am J Perinatol Date: 2016-10-07 Impact factor: 1.862
Authors: Christopher R Sudfeld; Quanhong Lei; Yvonne Chinyanga; Esther Tumbare; Nealia Khan; Fredrick Dapaah-Siakwan; Abia Sebaka; Jacinta Sibiya; Erik van Widenfelt; Roger L Shapiro; Joseph Makhema; Wafaie W Fawzi; Kathleen M Powis Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731